From 29f12744ca9379298bf026eba58ee6c410e8781f Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Thu, 21 Mar 2024 15:21:00 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web___Posts.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/pages/STOP2030___Web___Posts.md b/pages/STOP2030___Web___Posts.md index 664a2c71..f2ffa83e 100644 --- a/pages/STOP2030___Web___Posts.md +++ b/pages/STOP2030___Web___Posts.md @@ -3,7 +3,7 @@ - # REALISE study registration - ## The design of our REALISE study is now complete, and published - #+BEGIN_VERSE - At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). We are happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), a clinical trial aimed at evaluating safety and effectiveness within large populations. + At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). We are happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our largest clinical trial. The details of the REALISE study have been published in clinicaltrials.gov and the Pan African Clinical Trial Registry, and are now ready to be delivered to the Institutional Review Boards (IRBs) in Ghana and Kenya, the two countries were it will be carried out.